Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer.
Yuko WatanabeYoshitaka SaitoTakashi MitamuraYoh TakekumaMitsuru SugawaraPublished in: Journal of pharmaceutical health care and sciences (2021)
The results of the study suggest that adding aprepitant to palonosetron and DEX does not prevent carboplatin-induced nausea and vomiting in gynecologic cancer patients. Therefore, adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer.